Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Raw Materials: 2022-2025

Historic Raw Materials for Axsome Therapeutics (AXSM) over the last 3 years, with Sep 2025 value amounting to $12.4 million.

  • Axsome Therapeutics' Raw Materials rose 60.49% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year increase of 60.49%. This contributed to the annual value of $9.5 million for FY2024, which is 72.41% up from last year.
  • Per Axsome Therapeutics' latest filing, its Raw Materials stood at $12.4 million for Q3 2025, which was up 6.07% from $11.7 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Raw Materials registered a high of $12.4 million during Q3 2025, and its lowest value of $2.1 million during Q3 2022.
  • Over the past 3 years, Axsome Therapeutics' median Raw Materials value was $7.7 million (recorded in 2024), while the average stood at $7.7 million.
  • Data for Axsome Therapeutics' Raw Materials shows a peak YoY skyrocketed of 123.78% (in 2023) over the last 5 years.
  • Axsome Therapeutics' Raw Materials (Quarterly) stood at $2.5 million in 2022, then surged by 123.78% to $5.5 million in 2023, then surged by 72.41% to $9.5 million in 2024, then spiked by 60.49% to $12.4 million in 2025.
  • Its Raw Materials was $12.4 million in Q3 2025, compared to $11.7 million in Q2 2025 and $11.5 million in Q1 2025.